Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
Gilead Sciences Inc GILD
News
Championing HIV Services for LGBTQ+ Youth
Working to Build Next-Generation Cancer Therapies
Gilead's HIV-prevention drug cut infections by 96%, boosting stock
Helping End HIV - Gilead Sciences
Gilead’s Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Seramount Ranks Gilead Sciences Among Its Leading Inclusion Index Company
Gilead, Genesis Therapeutics to Use AI to Discover Novel Therapies
Gilead and Genesis Therapeutics Announce Strategic Collaboration to Discover and Develop Novel Therapies
Gilead Sciences: Living With a Rare Liver Disease: Maria's Journey
Gilead to Present New Trodelvy® Data at the IASLC 2024 World Conference on Lung Cancer
Gilead Sciences: Innovative Approaches to Healthcare Can Remove Barriers
Gilead Sciences Currently Up Nine Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
Gilead Sciences Currently Up Eight Consecutive Days, on Pace for Longest Winning Streak Since July 2023 — Data Talk
“The Adventure Jar,” Showcases a Family Navigating the Challenges of a Cancer Diagnosis and Finding Magic in Time Together
Gilead Sciences to Present at Upcoming Investor Conferences
Gilead Sciences: "One of Best Employers for Women" by Forbes
Building a Bridge to a Healthier World for Youth in Africa with Gilead Sciences
Gilead Sciences Receives Accelerated Approval from FDA
Gilead’s Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA
United States